Leishmaniasis in humans: drug or vaccine therapy?

Ghorbani, Masoud; Farhoudi, Ramin

Ghorbani, Masoud; Farhoudi, Ramin.

Affiliation

Ghorbani M; Department of Viral Vaccine Production, Pasteur Institute of Iran, Research and Production Complex, Karaj, Iran.
Farhoudi R; Department of Viral Vaccine Production, Pasteur Institute of Iran, Research and Production Complex, Karaj, Iran.

Drug Des Devel Ther ; 12: 25-40, 2018.

Article in En | MEDLINE | ID: mdl-29317800

Subject(s)

Antigens, Protozoan/therapeutic use; Leishmania/drug effects; Leishmaniasis Vaccines/therapeutic use; Leishmaniasis/drug therapy; Trypanocidal Agents/therapeutic use; Animals; Antigens, Protozoan/adverse effects; Antigens, Protozoan/immunology; Drug Resistance; Drug Therapy, Combination; Humans; Leishmania/immunology; Leishmaniasis/diagnosis; Leishmaniasis/immunology; Leishmaniasis/parasitology; Leishmaniasis Vaccines/adverse effects; Leishmaniasis Vaccines/immunology; Treatment Outcome; Trypanocidal Agents/adverse effects

Key words

leishmania; leishmania treatment; recombinant antigens; vaccine

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Trypanocidal Agents / Leishmaniasis / Leishmaniasis Vaccines / Leishmania / Antigens, Protozoan Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Journal: Drug Des Devel Ther Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2018 Document type: Article Affiliation country: Iran

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google